[
  {
    "ts": "2025-07-30T11:30:00+00:00",
    "headline": "Sensei Biotherapeutics to Present Clinical Data from the Phase 1 Dose Expansion Cohort of Solnerstotug at the ESMO Congress 2025",
    "summary": "BOSTON, July 30, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next generation therapeutics for cancer patients, announced today that clinical data from the dose expansion cohort of the Phase 1/2 trial of solnerstotug alone and in combination with Libtayo® (cemiplimab), Regeneron’s PD-1 inhibitor, will be presented in a mini oral session at the European Society for Medical Oncology (ESMO)",
    "url": "https://finance.yahoo.com/news/sensei-biotherapeutics-present-clinical-data-113000859.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "cc467561-fae1-334d-a424-c4163b7850b7",
      "content": {
        "id": "cc467561-fae1-334d-a424-c4163b7850b7",
        "contentType": "STORY",
        "title": "Sensei Biotherapeutics to Present Clinical Data from the Phase 1 Dose Expansion Cohort of Solnerstotug at the ESMO Congress 2025",
        "description": "",
        "summary": "BOSTON, July 30, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next generation therapeutics for cancer patients, announced today that clinical data from the dose expansion cohort of the Phase 1/2 trial of solnerstotug alone and in combination with Libtayo® (cemiplimab), Regeneron’s PD-1 inhibitor, will be presented in a mini oral session at the European Society for Medical Oncology (ESMO)",
        "pubDate": "2025-07-30T11:30:00Z",
        "displayTime": "2025-07-30T11:30:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/e973e812518a3b456c0f03b37c741f2e",
          "originalWidth": 1141,
          "originalHeight": 421,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/vSiv5Nql9xM_n1NJuROG.g--~B/aD00MjE7dz0xMTQxO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/e973e812518a3b456c0f03b37c741f2e.cf.webp",
              "width": 1141,
              "height": 421,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/iN2MO1gnUXX0n4ZE8mNypQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/e973e812518a3b456c0f03b37c741f2e.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/sensei-biotherapeutics-present-clinical-data-113000859.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/sensei-biotherapeutics-present-clinical-data-113000859.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "SNSE"
            },
            {
              "symbol": "REGN"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]